Literature DB >> 24685357

Glomus tumors in individuals with neurofibromatosis type 1.

Monique G Kumar1, Ryan J Emnett2, Susan J Bayliss1, David H Gutmann3.   

Abstract

BACKGROUND: Glomus tumors have recently been reported in individuals with the neurofibromatosis type 1 (NF1) cancer disposition syndrome. We compare the clinical and molecular features of these painful hamartomas in a series of sporadic and NF1-associated cases.
OBJECTIVE: We sought to evaluate the association of NF1 with glomus tumors and to compare NF1-associated glomus tumors with sporadic glomus tumors.
METHODS: We conducted a retrospective cohort study of all individuals with a histopathologic diagnosis of glomus tumor at a large tertiary care center from January 1998 to January 2013. Charts were reviewed for a coexisting diagnosis of NF1.
RESULTS: A total of 42 glomus tumors were identified in 34 individuals. Twelve (28.6%) were found in 6 patients with NF1. In 28 individuals with 30 sporadic tumors, there was no coexisting medical condition. Although multifocal tumors (16.7%) and tumor recurrence (33.3%) were more common in association with NF1, these trends did not reach statistical significance. NF1-associated glomus tumors exhibited no neurofibromin immunoreactivity, whereas their sporadic counterparts retained neurofibromin expression. LIMITATIONS: The retrospective design resulted in incomplete data capture.
CONCLUSIONS: Detection of glomus tumors should raise suspicion for a concurrent diagnosis of NF1.
Copyright © 2014 American Academy of Dermatology, Inc. Published by Mosby, Inc. All rights reserved.

Entities:  

Keywords:  glomus tumor; neurofibromatosis; neurofibromatosis type 1; neurofibromin; tumor disposition syndrome

Mesh:

Substances:

Year:  2014        PMID: 24685357     DOI: 10.1016/j.jaad.2014.01.913

Source DB:  PubMed          Journal:  J Am Acad Dermatol        ISSN: 0190-9622            Impact factor:   11.527


  5 in total

Review 1.  A RASopathy gene commonly mutated in cancer: the neurofibromatosis type 1 tumour suppressor.

Authors:  Nancy Ratner; Shyra J Miller
Journal:  Nat Rev Cancer       Date:  2015-04-16       Impact factor: 60.716

Review 2.  Current status and recommendations for imaging in neurofibromatosis type 1, neurofibromatosis type 2, and schwannomatosis.

Authors:  Shivani Ahlawat; Jaishri O Blakeley; Shannon Langmead; Allan J Belzberg; Laura M Fayad
Journal:  Skeletal Radiol       Date:  2019-08-08       Impact factor: 2.199

3.  Glomus tumor of the thenar eminence in neurofibromatosis type 1: case report and literature review.

Authors:  Gabriele Scaravilli; Roberto Rossi; Stefano Artiaco; Giovanni Merolla
Journal:  Transl Med UniSa       Date:  2014-12-19

4.  Neurofibromatosis 1 French national guidelines based on an extensive literature review since 1966.

Authors:  Christina Bergqvist; Amandine Servy; Laurence Valeyrie-Allanore; Salah Ferkal; Patrick Combemale; Pierre Wolkenstein
Journal:  Orphanet J Rare Dis       Date:  2020-02-03       Impact factor: 4.123

Review 5.  Glomus tumors around or in the knee: a case report and literature review.

Authors:  Yingjie Wang; Zehui Lv; Tian Li; Yanyan Bian; Bin Feng; Yong Liu; Xi Zhou; Xisheng Weng
Journal:  BMC Surg       Date:  2022-03-16       Impact factor: 2.102

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.